Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Brodalumab demonstrates positive results in plaque psoriasis studyA phase 3 trial of brodalumab (AMG 827) for the treatment of patients with moderate-to-severe plaque psoriasis demonstrated positive results, meeting primary and secondary endpoints.